XML 35 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies - Summary of Significant Accounts Receivable (Detail) (Accounts Receivable [Member])
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Gilead [Member]
   
Concentration Risk [Line Items]    
Significant Accounts Receivable 53.40%   
Pfizer [Member]
   
Concentration Risk [Line Items]    
Significant Accounts Receivable 12.30% 45.40%
Boehringer [Member]
   
Concentration Risk [Line Items]    
Significant Accounts Receivable 12.20% 18.00%
Eli Lilly [Member]
   
Concentration Risk [Line Items]    
Significant Accounts Receivable 7.00% 28.20%
Servier [Member]
   
Concentration Risk [Line Items]    
Significant Accounts Receivable 6.40%   
Government Agencies [Member]
   
Concentration Risk [Line Items]    
Significant Accounts Receivable 4.60% 8.40%